Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on October 15, 2013. The filing addresses Item 5.02 regarding the appointment of a new officer and the departure of an interim officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
- New Officer Salary: $285,000 annual salary for Michael A. Jacobsen.
- Equity Grant: Option to purchase 103,500 shares of common stock.
- Exercise Price: $9.37 per share.
Material Changes
On October 15, 2013, the Board of Directors appointed Michael A. Jacobsen as Vice President, Finance, and Chief Accounting Officer. He was designated as the company's principal financial officer and principal accounting officer. Concurrently, Gregory A. Demopulos, M.D. (President, CEO, and Chairman), ceased serving as the interim Chief Financial Officer and principal accounting officer.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business operations. It details the vesting schedule for Mr. Jacobsen's option award: 25% vests on September 3, 2014, with the remainder vesting in equal monthly installments over the following three years. The award includes change-in-control provisions that may accelerate vesting to 50% or 100% depending on the circumstances of the transaction and subsequent termination.
Important Facts for Investor Verification
- Confirmation that Gregory A. Demopulos has stepped down from the interim CFO role.
- Verification of Michael A. Jacobsen's background in biotechnology finance (Sarepta Therapeutics, ZymoGenetics, ICOS Corporation).
- Review of the specific vesting acceleration clauses in the 2008 Equity Incentive Plan regarding change-in-control events.
- Confirmation that no related-party transactions exist between Mr. Jacobsen and the company as of the filing date.